Brand and commercial-name modification evidence
qbd.brand-and-commercial-name-evidence
Annex 4 section 4.1 treats commercial-name changes separately from section 4.18 brand change/inclusion/exclusion. Commercial-name evidence includes updated Spanish labeling (with the biomedical-equipment marking exception), owner certification of the name change and unchanged quality/specifications, the specified domestic/foreign legal evidence, updated insert/manual/technical sheet, and legalized CLV bearing the new name. Brand evidence includes updated label, a justification letter issued by the titular or manufacturer, and, for foreign products when applicable, competent-authority CLV/equivalent declaring the new brand with the stated legalization.
Conditions
- The commercial-name and brand requirements must be applied to the actual change; neither is reduced to cosmetic NDM06 merely because the underlying device is unchanged.
- Bounded reading of the cited official original; no claim that every question aspect or later amendment has been exhausted.
Passage context: pdf-page-37 — Annex 4 sections 4.1 and 4.18; also pdf-page-38, pdf-page-43. See the independently pinned evidence references for every supporting page.
Modification filing framework and document formalities
qbd.dm01-modification-framework
DM01 Annex 4 requires the sanitary-registration holder to seek ARCSA authorization immediately with technical justification, electronically through VUE/ECUAPASS. Applicant data must match the operating permit and relevant activity. Technical documents are in Spanish or English and listed in an electronically signed letter from the Ecuador technical responsible person. Foreign legal documents require the stated apostille/consular formalities unless electronically issued and verifiable on the issuer website; other languages require the specified qualified translation. Listed modification cases do not themselves create a new registration number.
Conditions
- This is the February 2024 instruction under the 2016 norm as amended in 2023, not the norm taking effect in 2027.
- The quoted 2018-based 10% sentence is not used here as a universal 2026 fee; see the separately sourced 2026 tariff.
- Bounded reading of the cited official original; no claim that every question aspect or later amendment has been exhausted.
Passage context: pdf-page-36 — Annex 4 sections 2 and 4; also pdf-page-37. See the independently pinned evidence references for every supporting page.
DM02 permits modifications and notifications in the same application with each described in “Detalle de la modificación”; for a mixed filing do not enter NDM notification codes in “Código de referencia”, or the application is rejected. Section 5.1(d) limits a mixed filing to four modifications plus three notifications. Notification-only filings may list up to seven NDM codes separated by “/” without spaces. Mixed fees are based on the modifications; the review depends on complexity, risk and device type. Supporting documents remain required for every item.
Conditions
- This is a same-application limit, not proof that unrelated products, manufacturers or registrations may be combined.
- Bounded reading of the cited official original; no claim that every question aspect or later amendment has been exhausted.
Passage context: pdf-page-4 — Sections 3(c)-(g), 5.1(b)-(e); also pdf-page-5, pdf-page-6. See the independently pinned evidence references for every supporting page.
Annex 4 section 4.9 requires foreign competent-authority CLV/equivalent certifying the address change with legalization, ISO/BPM showing the new address, updated internal/external labels (biomedical marking exception), a manufacturer-address notification letter, and a domestic operating permit showing the new address for national manufacture. If the event also changes manufacturing process, the holder must file a process-update modification. Section 4.8 separately governs a product owner’s address when that owner is the principal manufacturer/site.
Conditions
- Do not equate a legal-office address change, physical factory relocation and new manufacturing-site inclusion. Resolve the actual actor and facility facts before selecting a case.
- Bounded reading of the cited official original; no claim that every question aspect or later amendment has been exhausted.
Passage context: pdf-page-40 — Annex 4 sections 4.8-4.9. See the independently pinned evidence references for every supporting page.
Annex 4 section 4.6 requires updated manufacturer-name labels (subject to the biomedical marking exception), foreign competent-authority CLV/equivalent certifying the company-name change with legalization or domestic chamber/mercantile evidence, a manufacturing contract bearing the new name when applicable, and the specified BPM/ISO 13485 evidence. The supporting quality certificate must justify the company-name change without change to the facilities’ address. This is distinct from replacing the principal manufacturer under section 4.3.
Conditions
- Actor is the manufacturer; do not substitute product-owner or registration-holder company-name requirements.
- Bounded reading of the cited official original; no claim that every question aspect or later amendment has been exhausted.
Passage context: pdf-page-39 — Annex 4 section 4.6; also pdf-page-40. See the independently pinned evidence references for every supporting page.
Annex 4 section 4.12 permits model-change modification only without affecting risk level, use or approved characteristics. It requires the manufacturer’s technical justification expressly addressing those points, updated internal/external labeling with the biomedical marking exception, and an insert with the new model. Annex 4 section 3 requires a new registration for the specified type/model/intended-use/conditions/composition/energy changes generating a risk-level change and for the stated formulated/drug-combination formula changes. DM02 explicitly defines its “Código de referencia” as an ARCSA service/form code unrelated to manufacturer product codes/references. No pure internal SMN/reference-change route is established by these passages.
Conditions
- The model must actually change; do not label an internal customer SMN as a model without product/dossier evidence.
- Bounded reading of the cited official original; no claim that every question aspect or later amendment has been exhausted.
Passage context: pdf-page-37 — Annex 4 section 3 and section 4.12; also pdf-page-42. See the independently pinned evidence references for every supporting page.
Office-address notifications depend on actor
qbd.ndm05-ndm07-office-actor-address
DM02 NDM05 covers a product-owner address change only when that owner is not the principal manufacturer or manufacturing site. Domestic evidence includes explanatory letter and operating permit at the new address; foreign evidence includes explanatory letter, competent-authority CLV/equivalent when applicable with the stated legalization/verifiable-electronic exception, and a power stating the new address and the holder’s powers. NDM07 covers a domestic registration-holder/applicant address only when it is not the principal manufacturer/site, with notification letter and updated operating permit. The corresponding manufacturer/site address cases are modifications under DM01.
Conditions
- An “office address” description alone does not establish notification eligibility. Resolve product owner versus holder/applicant versus actual manufacturer/site.
- Bounded reading of the cited official original; no claim that every question aspect or later amendment has been exhausted.
Passage context: pdf-page-8 — Table 1, NDM05 and NDM07; also pdf-page-9. See the independently pinned evidence references for every supporting page.
DM02 NDM06 covers label/insert/manual updates that do not modify approved information content and concern form only, except updates requested by ARCSA as stated in the table. For insert/manual and label changes, supply a detailed justification, a current/proposed comparison and the proposed insert/manual or label respectively. This source does not convert changed brand/manufacturer/model content into a cosmetic notification.
Conditions
- The no-impact notification definition and conditions in DM02 sections 2-5 apply.
- Bounded reading of the cited official original; no claim that every question aspect or later amendment has been exhausted.
Passage context: pdf-page-9 — Table 1, NDM06. See the independently pinned evidence references for every supporting page.
Stock notification after previously approved changes
qbd.ndm09-previously-approved-stock
DM02 NDM09 concerns stock exhaustion for changes previously approved. The table requires a justification letter describing the reason and the requirements established by the applicable current rule. This passage proves a conditional notification channel after change approval; it does not establish an automatic stock sell-through grace period, the permitted duration, or permission to implement an unapproved change.
Conditions
- Bounded reading of the cited official original; no claim that every question aspect or later amendment has been exhausted.
Passage context: pdf-page-9 — Table 1, NDM09; also pdf-page-10. See the independently pinned evidence references for every supporting page.
